knowledge -WSS

knowledge

author：focus 2025-09-28 00:49:25 - browse：5547

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Crinetics acromegaly drug succeeds in late

knowledge

WSS

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Stem cell clinics for heart failure: buyer be wary

Ethical issues complicate the benefits of medical crowdfunding

Stem cell clinics for heart failure: buyer be wary

The 10 drugs up first for Medicare price negotiation

What drug price negotiations mean for Medicare Part D

knowledge

knowledge

knowledge

Heart attack and stroke risk calculators need revising

A new House health package & hospitals’ new site

As demand for Covid shots wanes, Moderna seeks its next success

A rare thyroid diagnosis led to unexpected, all

Heart attack and stroke risk calculators need revising

Illumina names Agilent executive as new CEO

In age of alternative facts, a scholarly course on calling out crap

The (many) problems with a new study criticizing cancer screening

BioMarin wins approval for gene therapy to treat hemophilia A

Humana sues Biden admin over Medicare Advantage audit rule

hotspot

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

ALS advocates say criticism of new drugs misses bigger picture

What drug price negotiations mean for Medicare Part D

Nearly two

Covid hospitalizations on the rise, Humana says

Humana, CVS hope to turn members into patients at clinics

knowledge

focus

entertainment

explore